Racura Oncology completes first cohort dosing in RC220 Phase 1 trial with zero adverse events, advancing next-stage cancer treatment targeting heart-safe chemotherapy.
Core Lithium secures $120M equity funding and strategic backing to restart Finniss, targeting production by September 2026 amid improving lithium market outlook.
Mesoblast reports a 60% surge in Ryoncil sales, secures a US$125m facility, and expands into adult trials, signalling growing commercial momentum for the ASX-listed biotech.
DorsaVi (ASX: DVL) secures exclusive neuromorphic Processing-in-Memory technology from Technion, enabling self-learning biosensors and adaptive robotics. Stock jumps 12% as DVL enters the US$20Bn AI hardware market.
New Adiopan drilling delivers 16m @ 5.03g/t and more. Afema MRE update due; PFS targeting 2QCY2026 with ~A$80m cash for an expanded drill campaign.
NH3 signs MoU with MOL and Oceania to build clean ammonia bunkering at Dampier by 2030; targets 300ktpa demand and late-2026 FID for WAH2.
.webp&w=3840&q=75)
Aura Energy (ASX: AEE) progresses its Tiris Uranium Project in Mauritania, eyeing global supply chain opportunities. Learn more about the company’s latest updates and market positioning.
Inoviq Ltd shares jump 35.23% after unveiling promising early-stage ovarian cancer screening data at ASCO 2025. The EXO-OC™ test demonstrated 77% sensitivity and 99.6% specificity.
Dimerix Ltd (ASX:DXB) announces the activation of its first clinical site in Japan for the DMX-200 Phase 3 trial, unlocking a A$4.3M milestone payment from partner FUSO. Learn how this milestone supports Dimerix’s global growth strategy in treating FSGS.
Krakatoa Resources (ASX: KTA) advances its Zopkhito project in Georgia with an 11.6% antimony and 3.7g/t gold resource. As global antimony demand surges, KTA targets fast-tracked drilling, JORC conversion, and strategic offtake opportunities.
West African Resources (ASX: WAF) reports standout intercepts up to 44m @ 25.8 g/t gold at M1 South. A resource upgrade and 10-year production outlook are due in Q3 2025.
Omega Oil & Gas (ASX: OMA) confirms extensive oil and gas system at Canyon-2 with thicker, high-quality pay zones. Shares jump 11.91% as development momentum builds in the Taroom Trough.
Racura Oncology completes first cohort dosing in RC220 Phase 1 trial with zero adverse events, advancing next-stage cancer treatment targeting heart-safe chemotherapy.
Core Lithium secures $120M equity funding and strategic backing to restart Finniss, targeting production by September 2026 amid improving lithium market outlook.
Mesoblast reports a 60% surge in Ryoncil sales, secures a US$125m facility, and expands into adult trials, signalling growing commercial momentum for the ASX-listed biotech.
Krakatoa Resources (ASX: KTA) has launched diamond drilling at its Mt Clere Project targeting rare earth-rich intrusives. Backed by government funding, this move could elevate KTA’s role in Australia’s critical minerals supply chain.
Krakatoa Resources (ASX: KTA) begins a 7,000m drill program at its high-grade antimony-gold project in Georgia. Foreign resource includes 815,119oz gold and 26,000t Sb.
Enova Mining (ASX: ENV) submits Mining Management Plan for its Charley Creek rare earth project, receives feedback from NT government, and gears up for a bulk sampling trial.
The most important stories, delivered to your inbox. No noise, just what matters.
By subscribing, you agree to our Privacy Policy.
.webp&w=3840&q=75)
%252520Gears%252520Up%252520for%252520Major%252520Gold%252520%2526%252520Base%252520Metals%252520Discovery.png&w=3840&q=75)
%252520Gains%252520Momentum%252520with%252520FDA%252520Approval%252520of%252520RECELL%252520GO%252520Mini%252520(1).png&w=3840&q=75)
.png&w=3840&q=75)
%252520Strikes%252520Bonanza%25252047%252520%252520Antimony%252520at%252520Sunday%252520Creek%252520as%252520Critical%252520Minerals%252520Story%252520Gains%252520Momentum.webp&w=3840&q=75)